Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | GAK | O14976 | 3/20 | 1.00 |
| ▸ | ILK | Q13418 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL8413 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL3667407 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL30362833 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL29460839 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL1959332 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL28576829 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL16767632 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL18563 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL21176918 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL417841 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2557 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| EP-3277381-B1 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | OBI PHARMA INC (TW) | 2026-01-07 | — | — | EP | claimed |
| US-20250388573-A1 | FUSED BICYCLIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2025-12-25 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250241923-A1 | A DUAL SELECTIVE PI3K DELTA AND GAMMA INHIBITORS AND/OR A SALT-INDUCIBLE KINASE 3 INHIBITOR FOR TREATING SOLID TUMORS | Incozen Therapeutics Pvt. Ltd (IN) | 2025-07-31 | — | — | US | claimed |
| EP-4577832-A1 | METHOD FOR PREDICTING THE RESPONSE TO AN INHIBITOR OF EGFR KINASE ACTIVITY | Indivumed GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| US-20250179524-A1 | RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-06-05 | — | — | US | claimed |
| US-20220265592-A1 | USE OF BIPOLAR TRANS CAROTENOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR TREATMENT OF CANCER | DIFFUSION PHARMACEUTICALS LLC | 2022-08-25 | — | — | US | claimed |
| WO-2022165398-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | WO | claimed |
| CN-114828842-A | Composition comprising DHODH inhibitor for the treatment of acute myeloid leukemia | 理森制药股份公司 | 2022-07-29 | — | — | CN | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| WO-2022140289-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | CORNELL UNIVERSITY (US) | 2022-06-30 | — | — | WO | claimed |
| EP-4010072-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW Bio, LLC (US) | 2022-06-15 | — | — | EP | claimed |
| CN-108424454-B | Monoclonal antibody 175 targeting EGF receptor, and derivatives and uses thereof | 路德维格癌症研究所有限公司 | 2022-05-31 | — | — | CN | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | claimed |
| US-20220056475-A1 | RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER | 2022-02-24 | — | — | US | claimed |